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Myeloablative and Reduced-Intensity Conditioning
in Patients with Major Histocompatibility Complex
Class II Deficiency
Hamoud Al-Mousa,1 Zamil Al-Shammari,1 Abdulaziz Al-Ghonaium,1 Hasan Al-Dhekri,1
Saleh Al-Muhsen,1,2 Bander Al-Saud,1 Rand Arnaout,1 Amal Al-Seraihy,3 Abdullah Al-Jefri,3
Ali Al-Ahmari,3 Mouhab Ayas,3 Hassan El-Solh3Major histocompatibility complex class II (MHC II) deficiency is a rare combined immunodeficiency disease.
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment. Between June 1994
and February 2007, 30 childrenwithMHC II deficiency underwent a total of 33HSCTprocedures. Median age
at HSCTwas 27 months. The stem cell source was unmanipulated bone marrow from HLA-identical related
donors in 26 patients, one HLA antigen-mismatched bone marrow in 3 patients, and unrelated umbilical cord
blood in 1 patient. Conditioning was with one of 3myeloablative regimens—regimen A (18 patients): busulfan
(Bu), cyclophosphamide (Cy), and etoposide; regimen B (2 patients): Bu, Cy, and antithymocyte globulin
(ATG); or regimen C (1 patient): CY and total body irradiation (TBI)—or with a reduced-intensity regimen
(12 patients): fludarabine, melphalan, and ATG. Themedian CD34 cell dosewas 8.3 106/kg. Twenty patients
experienced immune reconstitution and had sustained engraftment ranging from 9% to 100% for lymphoid
lines and from 5% to 100% for myeloid lines that were significant to cure the disease. The overall disease-
free survival rate was 66% and 76% after HLA-identical HSCT, with a median follow-up of 6.3 years, which
is higher than previously reported. InHLA-identical transplant recipients, reliable donor stemcell engraftment
and immune reconstitution were achieved through myeloablative or reduced-intensity conditioning. Further
studies and long-term follow-up are needed to determine the appropriate conditioning regimen.
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ImmunodeficiencyINTRODUCTION
Major histocompatibility complex class II (MHCII)
deficiency is a rare combined immunodeficiency disease
characterized by profoundly deficient human leukocyte
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The disease is also referred to as bare lymphocyte syn-
drome type II. Clinical manifestations include extreme
susceptibility to viral, bacterial, fungal, and protozoal
infections, primarily of the respiratory and gastrointes-
tinal tract. Severe malabsorption with failure to thrive
ensues, often leading to death in early childhood [1-4].
The disease is an autosomal recessive disease re-
sulting from defects in several distinct transacting reg-
ulatory factors required for the expression of MHC II
genes. This deficiency is classified into 4 complemen-
tation groups. Mutations in CIITA (complementation
group A), RFXANK (complementation group B),
RFX5 (complementation group C), and RFXAP (com-
plementation groupD) have been identified in individ-
uals with MHC II deficiency [4].
Allogeneic hematopoietic stem cell transplantation
(HSCT) is considered the only available curative treat-
ment for MHC II deficiency. HSCT can cure the
disease, provided that it is performed before the
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failure [5,6]. In the European registry data, HSCT in
patients with MHC class II deficiency was associated
with a lower survival rate than HSCT performed
for other primary immunodeficiencies [6,7]. These
differences were observed for HSCT performed
with matched and nonmatched donors alike, and
MHC class II immunodeficiency seemed to carry
a poor prognosis, especially after HLA nonidentical
transplantation, with only 32% of patients surviving
to 1 year [6]. The low survival after HLA-identical
HSCT (53%) was likely related to the incidence of
preexisting viral infections and was associated with
a high incidence of acute graft-versus-host disease
(aGVHD) [8]. An interesting observation in long-
term transplantation survivors is the persistence of
a relative CD4 T cell lymphopenia, possibly because
of a lack ofHLA class II molecules on thymic epithelial
cells [5].
Given the available HSCT protocols for children
with MHC II deficiency, intensive pretransplantation
conditioning appears to be a prerequisite for reliable
engraftment and complete immune reconstitution.
But, this conditioning is associated with an increased
risk of short-term and long-term toxicity, particularly
infections and end-organ decompensation, leading to
a high rate of treatment-related mortality, especially
in older children who acquire organ dysfunction.
Late adverse effects, including growth retardation,
infertility, and secondary malignancies, also are of
concern.
Driven by concerns about myeloablative (MA)
regimens, some groups have reported success using
reduced-intensity conditioning (RIC) regimens in pa-
tients with hematologic malignancies [9-11]. Recent
reports of RIC regimen-based HSCT in patients
with primary immunodeficiencies and significant
organ dysfunction indicated good engraftment and
immune reconstitution with minimal toxicity and
GVHD [12]. In one series, high-risk patients treated
with RIC-based HSCT had better survival than those
treated with MA HSCT (94% vs 53%) [13]. Here we
describe the outcomes of a large series of patients
with MHC II deficiency who underwent HSCT at
a single center using MA conditioning and RIC.PATIENTS AND METHODS
Patient Characteristics
Between June 1994 and February 2007, 30 chil-
dren with MHC II deficiency underwent 33 HSCT
procedures at King Faisal Specialist Hospital and Re-
search Center (KFSHRC) in Riyadh, Saudia Arabia.
Three patients required a second HSCT trial. A retro-
spective chart review was conducted with multivariate
factors including pre-HSCT clinical and immunologiccharacteristics, HSCT characteristics (ie, age at
HSCT; donor status including age, sex, and HLA
match; serologic status; conditioning regimen; toxic-
ity; stem cell origin; CD341 cells dose infused; bone
marrow manipulation; engraftment; GVHD; infec-
tions; and outcome), and immune reconstitution
post-HSCT at last follow-up. The diagnosis was
made through the analysis of MHC-II expression on
peripheral blood monocytes, B cells, and activated T
cells. Assessment of isolated pathogens was made
through culture or polymerase chain reaction (PCR)
of material obtained by specimen collection or biopsy.
The study was approved by KFSHRC’s Institutional
Review Board.Preparative Regimen, Transplantation,
and Supportive Care
Conditioning therapy consisted of one of 3 MA
regimens—regimen A (18 patients): busulfan (Bu)
16 mg/kg (days -10 to -7), cyclophosphamide (Cy)
200 mg/kg (days -5 to -2), and etoposide (VP-16)
300 mg/m2/day (days -5 to -3), regimen B (2 patients):
Bu, Cy, and antithymocyte globulin (ATG) 5 mg/kg/
day (days -5 to -2), or regimen C (1 patient): Cy and
total body irradiation (TBI)—or a RIC regimen (12
patients) comprising fludarabine 30 mg/m2 /day
(days -7 to -3), melphalan 140 mg/m2 (day -2), and
ATG 5mg/kg/day (days -2 to12). The stem cell sour-
ces were unmanipulated bonemarrow fromHLA-gen-
oidentical siblings in 19 patients, HLA-phenotypically
identical related donors in 7 patients, one antigen
HLA-mismatched related donors in 3 patients, and
unrelated umbilical cord blood in 1 patient. HLA-
compatibility was assessed serologically at class 1 (A,
B, and C loci) and molecularly at class 2 (DRB1 and
DQB1 loci). The total number of CD341 stem cells
infused on the day of transplantation ranged from
3 to 20.7  106/kg (median, 8.7  106/kg). GVHD
prophylaxis consisted of cyclosporine (CsA) and meth-
otrexate (MTX) in 17 patients, CsA alone in 15 pa-
tients, and CsA and a steroid in 1 patient. All patients
were placed in a positive-pressure isolation room.
Febrile illnesses during periods of aplasia were treated
with standard preemptive intravenous antibiotherapy.
Hematologic support with matched erythrocytes and
platelets was provided where indicated. All blood
products were irradiated and were cytomegalovirus
(CMV)-negative for CMV-negative patients. Detec-
tion of CMV in the donor or the recipient before
transplantation led to preemptive treatment with in-
travenous acyclovir (1500 mg/m2/day) for 60 days.
All patients received granulocyte colony-stimulating
factor 5 mg/kg per day from day 18 until absolute
neutrophil count (ANC) recovered to .0.5  109/L.
Intravenous immunoglobulin was administered once
every 3 weeks.
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Engraftment was confirmed by the presence of
MHC-II expression on peripheral blood monocytes,
B lymphocytes, and activated T lymphocytes. Chime-
rism was tested by short tandem repeat typing. Pheno-
typing of circulating peripheral blood mononuclear
cells was performed by 3-color immunofluorescence
with flow cytometry using monoclonal antibodies spe-
cific for CD3, CD4, CD8, and CD19. T cell function
was determined in vitro by proliferative responsiveness
to phytohemagglutinin and tetanus toxoid stimulation.
Serum Ig level was measured by nephelometry.
The diagnosis of aGVHD and/or chronic GVHD
(cGVHD) was made according to the established con-
sensus criteria for GVHD grading [14] and confirmed
when necessary by biopsy and pathological analysis. All
patients were treated with corticosteroids and received
additional immunomodulatory therapy as needed.RESULTS
Pretransplantation Clinical and Immunologic
Characteristics
Pretransplantation clinical and immunologic char-
acteristics are summarized in Tables 1 and 2. The
study group comprised 19 males and 11 females,
with a median age at diagnosis of 16 months (range,
1 week to 114 months). Recurrent chest infections,
chronic diarrhea, and failure to thrive were the most
common clinical manifestations. Most patients had
evidence of an active infection or a pathogen,
including CMV (n 5 7), Epstein-Barr virus (EBV)
(n 5 2), Pneumocystis jiroveci (n 5 3), enterovirus (n 5
2), and cryptosporidiosis (n 5 2). MHC II expression
was absent on B cells and activated T cells in all
patients, and variable hypogammaglobulinemia wasTable 1. Clinical and Immunologic Characteristics Pre-HSCT
Characteristic
Age, mean (range)
Sex
Chest infections, n*
Protracted diarrhea, n*
Hepatitis/cholangitis, n*
CMV, n*
Pneumocystis jiroveci pneumonia, n*
EBV, n*
Enterovirus, n*
Cryptosporidiosis, n*
IgG, g/L, range (median)
CD3 cells/mm3, range (median)
CD4 cells/mm3, range (median)
CD19 cells/mm3, range (median)
MHC II expression (% positive cells)†
Lymphocyte response to phytohemagglutinin, cpm, range (median)
Lymphocyte response to tetanus texoid, cpm, range (median)
HSCT indicates hematopoietic stem cell transplantation; CMV, cytomegalovir
*Patients positive/total patients.
†MHC II expression was evaluated on B cells (B) and activated T cells (act)seen. Three patients were diagnosed on newborn
screening because of a family history of MHC II
deficiency. The median age at HSCT was 27 months
(range, 1-120 months).Survival and Toxicity
Transplantation-related complications are sum-
marized in Table 2. Suspected veno-occlusive liver dis-
ease (n5 1) and significant hepatotoxicity (n5 2) were
seen in the MA group. With regard to infections, all
patients experienced more than one episode of neutro-
penic fever that was treated with standard preemptive
intravenous antibiotherapy and adjusted according to
culture results. CMV reactivation occurred in 8 pa-
tients (6 with MA conditioning and 2 with RIC) and
was treated with anti-CMV therapy. Suspected fungal
sinus infections were observed in 5 patients. Four pa-
tients died, including 3 patients in the MA group (2 af-
ter second HSCT and 1 after unrelated umbilical cord
blood transplant) secondary to chemotherapy-related
toxicity, sepsis, and multiorgan failure and 1 patient
in the RIC group secondary to bacterial sepsis.
The overall disease-free survival was 66% (20/30)
and 76% (20/26) after HLA-identical HSCT, with
a median follow-up of 6.3 years which is higher than
previously reported [8] (Figure 1). No significant dif-
ferences in disease free-survival after HLA-identical
HSCT based on conditioning regimen (MA or RIC)
or age at HSCT (\1 year or .1 year) were seen. All
3 patients who underwent HSCT from a one anti-
gen-mismatched donor using an RIC regimen rejected
their grafts despite primary engraftment. Two of the 3
patients who were diagnosed early in life because of
family history of the disease and underwent preemp-
tive HSCT before the development of symptomatic
infections rejected their grafts, and 1 of them died after
a second HSCT.Value Normal Range
16 months (1 week to 114 months)
19 M/11 F -
27/30 -
26/30 -
4/30 -
7/30 -
3/30 -
2/30 -
2/30 -
2/30 -
1.4-16.4 (4.7) 3.5-12.4
470-5294 (2461) 2200-4100
118-2106 (946) 1400-2800
100-1716 (951) 700-1600
< 1% -
9022-270,063 (85,565) 94,935-171,149
169-350 (224) 6790-54,368
us; EBV, Epstein-Barr virus; MHC, major histocompatibility complex.
Table 2. Stem Cell Transplantation Characteristics
Myeloablative RIC
Age at HSCT, months, range (median) 1-44 (14.4) 2-120 (43.3)
HLA match, n
10/10 S, 14 10/10 S, 3
10/10 R, 5 10/10 R, 5
8/10 UC, 1 9/10 R, 3
CD34 dose/kg, range (median) 3-20.7  106 (9.3) 4.1-11  106 (7.7)
Stem cell source Bone marrow Bone marrow
GVHD, n
Acute Skin, 9 Skin, 7
Gut, 5
Lung, 1
Chronic Skin, 3
Gut, 2
ANC >500, days, range (median) 10-43 (17.6) 11-16 (13)
Platelets > 20  109/L, days, range (median) 11-78 (25.2) 15-85 (28.7)
Veno-occlusive disease, n 1 -
Hepatotoxicity, n 2 -
CMV, n 6 2
Mortality, n 3 1
HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; ANC, absolute neutrophil count; CMV, cytomegalovirus;
RIC, reduced-intensity conditioning; S, sibling; R, related; UC, unrelated umbilical.
HLA identity is based on HLA-A, -B, -C, -DR, and -DQ determination.
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The median time to neutrophil recovery to ANC
.0.5  109/L was 17.6 days (range, 10-43 days) for
the MA group and 13 days (range, 11-16 days) for
the RIC group. The median time to an unsupported
platelet count of .20  109/L was 25.2 days (range,
11 to 78 days) for the MA group and 28.7 days (range,
15-85 days) for the RIC group (Table 2). Our chime-
rism data demonstrate that 20 patients had sustained
mixed hematopoietic chimerism, with donor lympho-
cyte cell chimerism ranging from 9% to 100% and do-
nor myeloid cell chimerism ranging from 5% to 100%.
The median lymphocyte cell and myeloid cell chime-
rism were 68% and 63%, respectively, with a median
follow-up of 79 months in the MA group, and 42%
and 22% with a median of follow-up of 35 months in
the RIC group.
GVHD
Variable degrees of aGVHDwere seen in the mye-
loablative group involving skin (n 5 9; grade II-III),
gut (n 5 5; grade II-III), and lung (n 5 1). Three pa-
tients developed cGVHD (n 5 2 skin and gut; n 5 1
skin). Seven patients in the RIC group developed grade
I-II acute skin aGVHD with no other organ involve-
ment that responded well to standard steroid therapy.
No patient developed cGVHD.
Immune Reconstitution
Twenty patients (66%) (76% post HLA-identical
HSCT) has sustained engraftment and immune recon-
stitution. Immune reconstitution in the MA and RIC
groups are summarized in Table 3. Patients achieved
normal lymphocyte counts by 3-6 months post-
HSCT. Variable CD4 lymphopenia was observed,
with a median value of 617 cells/mm3. T cell reconsti-tution was confirmed in all patients through the estab-
lishment of MHC II expression on activated T cells.
Lymphocyte proliferation to mitogens normalized,
whereas response to antigens improved but remained
subnormal in both groups. Despite variable donor B
cell engraftment, B cell counts returned to normal
within weeks or months. IgG level normalized in all
patients, and intravenous immunoglobulin therapy
was discontinued. All patients mounted a protective
antibody response by 6 weeks postvaccination to 3
doses of tetanus vaccine (representative of protein an-
tigen) and 1 dose of unconjugated pneumococcal
(polysaccharide) vaccine.
Clinical Course and Infections
At the time of this report, 20 patients were alive
and well. All patients were able to clear their chronic
infections. None had developed a severe infection,
and those patients with preexisting bronchiectasis
and chronic lung disease demonstrated some clinical
improvement, with mild intermittent chest exacerba-
tions treated successfully with oral antibiotics.
Second HSCT
Two patients who underwent a second HSCT us-
ing MA conditioning (Bu, Cy, and ATG, and Cy and
TBI) died secondary to chemotherapy toxicity, sepsis,
and multiorgan failure. One patient who underwent
retransplantation 7 years after the first transplantation
with a RIC regimen had sustained engraftment and
immune reconstitution.DISCUSSION
The high rate of consanguinity in Saudi Arabia has
resulted in an increased incidence of primary
Figure 1. Disease free survival post-HSCT (group 1, all patients; group 2, HLA-identical).
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ciency. Little is known about the molecular aspects
of this disease in Saudi Arabia. MHC deficiency is
seen predominantly in 2 Saudi tribes, and it will be
of interest to study the underlying genetic defects in
our patients to assess for a possible predominant muta-
tion in this population and to explore whether the
genotype has any effect on the outcome of HSCT.
This study provides the largest series to date of
patients with MHC II deficiency who underwent allo-
geneic HSCT at a single center. Patients who under-
went HSCT with standard Bu/Cy conditioning
regimens had higher donor cell engraftment, suggest-
ing that this might be a reasonable standard regimen
for HSCT in patients with MHC II deficiency. An
RIC regimen may be particularly suited for patients
with comorbid conditions, many of whom are referred
for allogeneic HSCT when critically ill with a dissem-
inated infection.
HSCT using an RIC regimen was well tolerated
and carried a lower incidence of infective complica-
tions and less-severe GVHD compared with HSCTTable 3. Immune Reconstitution on Last Follow-Up
Time post-HSCT, months, range (median)
Chimerism, %, range (median)
Lymphocytes
Myeloid
CD3 cells/mm3, range (median)
CD4 cells/mm3, range (median)
Total MHC II, range (median)*
CD19 cells/mm3 (median)
MHC II/CD19, range (median)
IgG, g/L, range (median)
Protective antibody response to tetanus, n
Protective antibody response to unconjugated pneumococcal vaccine, n
Phytohemagglutinin, cpm, range (median) 36,4
Tetanus, cpm, range (median)
HSCT indicates hematopoietic stem cell transplantation; MHC, major histoco
*Absolute number of MHC II+ cells/mm3, including B cells and activated T cel
†Patients positive/total patients.with a standard Bu/Cy conditioning regimen. Even
though this finding is encouraging, it is limited by
the short follow-up; further studies are merited to fol-
low our cases and assess the long-term stability of the
grafts in both regimens.
We found a 76% disease-free survival rate in our
patients with MHC II deficiency who underwent
HLA-identical related transplants, which is higher
than reported previously [8]. A significant incidence
of mixed chimerism was seen in both the MA and
RIC groups; however, it is well established that mixed
chimerism is sufficient to cure the disease. Interest-
ingly, CD4 T cell lymphopenia persisted after
HSCT and was not influenced by the type of condi-
tioning used, possibly reflecting impaired thymic mat-
uration of CD4 T cells because of decreased MHC II
expression in thymic epithelium. The fact that our pa-
tients were able to clear viral infections (CMV, EBV,
rotavirus, and enterovirus) and cryptosporidiosis at-
tests to a significant recovery of functional immunity.
Despite variable donor B cell engraftment, all patients
were able to produce normal IgG, IgA, and IgM levelsMyeloablative RIC Normal Range
44-122 (79) 25-44 (35) -
9%-100% (68%) 14%-84% (42%) -
5%-100% (63%) 10%-45% (22%)
986-4888 (2212) 1423-2253 (1752) 2200-4100
315-1183 (662) 294-914 (564) 1400-2800
79-1544 (651) 165-2427 (714) -
96-1125 (514) 110-812 (620) 700-1600
32-1029 (349) 37-218 (104) 700-1600
6.2-14.5 (10.4) 6.6-17.3 (10.7) 3.5-12.4
13/13† 7/7† -
13/13† 7/7† -
60-190,362 (82,543) 59,193-162,217 (112,113) 94935-171,149
269-11,262 (3249) 1005-9476 (4226) 6790-54,368
mpatibility complex; RIC, reduced-intensity conditioning.
ls.
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vivo specific antibody responses to immunization con-
firms the restoration of B cell function.
In summary, we have demonstrated that reliable
donor stem cell engraftment and immune reconstitu-
tion after HLA-identical HSCT can be achieved
with either an MA conditioning regimen or an RIC
regimen. RIC is associated with a high rate of rejection
in mismatched transplants. A high mortality rate was
seen after second HSCT. Further studies and long-
term follow-up are needed to determine the appropri-
ate conditioning regimen.ACKNOWLEDGMENTS
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